PL361874A1 - Terapia skojarzona w leczeniu chorób estrogenowrażliwych - Google Patents

Terapia skojarzona w leczeniu chorób estrogenowrażliwych

Info

Publication number
PL361874A1
PL361874A1 PL01361874A PL36187401A PL361874A1 PL 361874 A1 PL361874 A1 PL 361874A1 PL 01361874 A PL01361874 A PL 01361874A PL 36187401 A PL36187401 A PL 36187401A PL 361874 A1 PL361874 A1 PL 361874A1
Authority
PL
Poland
Prior art keywords
estrogen
treatment
combination therapy
sensitive disease
disease
Prior art date
Application number
PL01361874A
Other languages
English (en)
Inventor
S.Mark Moran
Peter Langecker
Original Assignee
Biomedicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedicines, Inc. filed Critical Biomedicines, Inc.
Publication of PL361874A1 publication Critical patent/PL361874A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL01361874A 2000-10-06 2001-10-03 Terapia skojarzona w leczeniu chorób estrogenowrażliwych PL361874A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23877200P 2000-10-06 2000-10-06
PCT/US2001/031060 WO2002030429A1 (en) 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease

Publications (1)

Publication Number Publication Date
PL361874A1 true PL361874A1 (pl) 2004-10-04

Family

ID=22899242

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01361874A PL361874A1 (pl) 2000-10-06 2001-10-03 Terapia skojarzona w leczeniu chorób estrogenowrażliwych

Country Status (14)

Country Link
US (5) US20020119502A1 (pl)
EP (1) EP1330251A4 (pl)
JP (1) JP2004510994A (pl)
CN (1) CN1471400A (pl)
AU (1) AU2001296578A1 (pl)
BR (1) BR0114655A (pl)
CA (1) CA2424299A1 (pl)
HU (1) HUP0301276A2 (pl)
IL (1) IL155237A0 (pl)
MX (1) MXPA03003032A (pl)
NZ (1) NZ525105A (pl)
PL (1) PL361874A1 (pl)
RU (1) RU2003112974A (pl)
WO (1) WO2002030429A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002342335B2 (en) * 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US20120230914A1 (en) * 2009-07-03 2012-09-13 Riken Labeling compound for pet
RU2413546C1 (ru) * 2009-09-17 2011-03-10 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН (РОНЦ им. Н.Н. Блохина РАМН) Способ лечения экстраабдоминальных десмоидных опухолей
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3384282A1 (en) * 2015-11-30 2018-10-10 Pharnext Method for adapting doses of combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites

Also Published As

Publication number Publication date
CN1471400A (zh) 2004-01-28
CA2424299A1 (en) 2002-04-18
US20050130945A1 (en) 2005-06-16
BR0114655A (pt) 2004-02-10
MXPA03003032A (es) 2003-06-06
EP1330251A1 (en) 2003-07-30
HUP0301276A2 (hu) 2003-11-28
US20050228053A1 (en) 2005-10-13
US20020119502A1 (en) 2002-08-29
US20050232862A1 (en) 2005-10-20
NZ525105A (en) 2004-10-29
US20050176691A1 (en) 2005-08-11
EP1330251A4 (en) 2006-03-15
WO2002030429A1 (en) 2002-04-18
RU2003112974A (ru) 2004-11-27
JP2004510994A (ja) 2004-04-08
AU2001296578A1 (en) 2002-04-22
IL155237A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0500424A2 (en) Combination therapy for the treatment of cancer
GB0004531D0 (en) The treatment of respiratory diseases
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB0001710D0 (en) Therapeutic treatment
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
IL142581A (en) Medicament for treating heart disease
AU2096002A (en) Therapeutic treatment
GB0029524D0 (en) Disease treatment
GB0128628D0 (en) Disease treatment
GB2397018B (en) Combination therapy for treating disease
HK1057996A (en) Combination therapy for the treatment of estrogen-sensitive disease
GB0128122D0 (en) Therapeutic use
GB9919565D0 (en) Treatment of disease
SI1242060T1 (sl) Zdravljenje metastatske bolezni
GB0119164D0 (en) Skin disease treatment
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
AU2638002A (en) Tissue treatment
GB0130191D0 (en) Therapeutic treatment
ZA200304439B (en) Therapeutic treatment.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)